Patents by Inventor Daniel Levin

Daniel Levin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11078220
    Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: August 3, 2021
    Assignee: Mallinckrodt Hospital Products IP Limited
    Inventors: George S. Drummond, Robert Caroselli, Keith A. Cooke, Daniel Levin, David G. Roe, Christopher P. Boucher
  • Patent number: 11013804
    Abstract: The present invention provides for a perillyl alcohol (POH) carbamate, such as POH-Rolipram. The present invention also provides for a method of treating a disease such as cancer, by delivering to a patient a therapeutically effective amount of POH-Rolipram.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: May 25, 2021
    Assignee: NeOncTechnologies, Inc.
    Inventors: Thomas Chen, Daniel Levin, Satish Pupalli
  • Publication number: 20210130271
    Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.
    Type: Application
    Filed: December 16, 2020
    Publication date: May 6, 2021
    Inventors: Thomas CHEN, Daniel LEVIN, Satish PUPPALI
  • Patent number: 10899691
    Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: January 26, 2021
    Assignee: NeOnc Technologies, Inc.
    Inventors: Thomas Chen, Daniel Levin, Satish Puppalli
  • Publication number: 20200277299
    Abstract: A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.
    Type: Application
    Filed: May 18, 2020
    Publication date: September 3, 2020
    Inventors: Thomas CHEN, Daniel LEVIN, Satish Puppali
  • Publication number: 20200255458
    Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.
    Type: Application
    Filed: May 1, 2020
    Publication date: August 13, 2020
    Inventors: George S. Drummond, Robert Caroselli, Keith A. Cooke, Daniel Levin, David G. Roe, Christopher P. Boucher
  • Publication number: 20200237697
    Abstract: The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of a perillyl alcohol derivative such as a perillyl alcohol ester, or an isoperillyl alcohol derivative such as an isoperillyl alcohol ester. The derivative may be a perillyl alcohol or an isoperillyl alcohol conjugated with a therapeutic agent such as valproic acid. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.
    Type: Application
    Filed: April 18, 2018
    Publication date: July 30, 2020
    Inventors: Thomas CHEN, Daniel LEVIN, Satish PUPALLI
  • Patent number: 10696680
    Abstract: A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: June 30, 2020
    Assignee: NeOnc Technologies, Inc.
    Inventors: Thomas Chen, Daniel Levin, Satish Puppali
  • Publication number: 20200172557
    Abstract: Au(III) complexes for [18F] trifluoromethylation and methods for producing the same are disclosed. A gold complex comprises Au(CF3)2LR, wherein L comprises a solubility supporting ligand and R comprises an organic substituent. The Au(III) complex can be used to prepare a positron emitting isotope that can be used as tracers for positron emitting tomography (PET) scans.
    Type: Application
    Filed: May 21, 2018
    Publication date: June 4, 2020
    Inventors: F. Dean Toste, Mark Daniel Levin, James Patrick O'Neil
  • Publication number: 20200170961
    Abstract: The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of an isomer or analog of monoterpene or sesquiterpene (or its derivative), such as an isoperillyl alcohol. The present invention also provides for a method of treating a disease comprising the step of administering to a patient a therapeutically effective amount of a derivative of an isomer or analog of monoterpene or sesquiterpene, such as an isoperillyl alcohol carbamate. The derivative may be an isoperillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.
    Type: Application
    Filed: November 6, 2019
    Publication date: June 4, 2020
    Inventors: Thomas Chen, Daniel Levin, Satish Pupalli, Daniel Anthony Dickman
  • Patent number: 10662209
    Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: May 26, 2020
    Assignee: Mallinckrodt Hospital Products IP Limited
    Inventors: George S. Drummond, Robert Caroselli, Keith A. Cooke, Daniel Levin, David G. Roe, Christopher P. Boucher
  • Publication number: 20200131106
    Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.
    Type: Application
    Filed: September 19, 2019
    Publication date: April 30, 2020
    Inventors: Thomas CHEN, Daniel LEVIN, Satish PUPALLI
  • Publication number: 20200078462
    Abstract: The present invention provides for a perillyl alcohol (POH) carbamate, such as POH-Rolipram. The present invention also provides for a method of treating a disease such as cancer, by delivering to a patient a therapeutically effective amount of POH-Rolipram.
    Type: Application
    Filed: April 18, 2019
    Publication date: March 12, 2020
    Inventors: Thomas CHEN, Daniel Levin, Satish Pupalli
  • Publication number: 20200078355
    Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.
    Type: Application
    Filed: April 15, 2019
    Publication date: March 12, 2020
    Inventors: Thomas CHEN, Daniel LEVIN, Satish PUPALLI
  • Patent number: 10570105
    Abstract: The present invention includes methods/processes and intermediates for preparing compounds having structural Formula (XI): wherein Y is C1-C12 alkylene or C1-C12 alkenylene; and R8 and R12 are independently C1-C12 alkyl.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: February 25, 2020
    Assignee: Firmenich Incorporated
    Inventors: Catherine Tachdjian, Donald S. Karanewsky, Xiao-Qing Tang, Qing Chen, Peter Leeming, Tayyab Rashid, Daniel Levin
  • Patent number: 10457618
    Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: October 29, 2019
    Assignee: NeOnc Technologies, Inc.
    Inventors: Thomas Chen, Daniel Levin, Satish Puppali
  • Publication number: 20190275031
    Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.
    Type: Application
    Filed: September 6, 2018
    Publication date: September 12, 2019
    Inventors: Thomas CHEN, Daniel LEVIN, Satish PUPALLI
  • Patent number: 10399920
    Abstract: Crystalline Cannabidiol of a novel form, including (R,R)-(?)-crystalline Cannabidiol, as well as methods of making such novel form of Cannabidiol, pharmaceutical formulations comprising such novel form of Cannabidiol, and methods of treating diseases with such novel form of Cannabidiol.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: September 3, 2019
    Assignee: S&B Pharma, Inc.
    Inventors: Daniel Dickman, Daniel Levin
  • Publication number: 20190263762
    Abstract: The present invention includes methods/processes and intermediates for preparing compounds having structural Formula (XI): wherein Y is C1-C12 alkylene or C1-C12 alkenylene; and R8 and R12 are independently C1-C12 alkyl.
    Type: Application
    Filed: May 9, 2019
    Publication date: August 29, 2019
    Inventors: Catherine Tachdjian, Donald S. Karanewsky, Xiao-Qing Tang, Qing Chen, Peter Leeming, Tayyab Rashid, Daniel Levin
  • Publication number: 20190241568
    Abstract: A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.
    Type: Application
    Filed: September 10, 2018
    Publication date: August 8, 2019
    Inventors: Thomas CHEN, Daniel LEVIN, Satish Puppali